Takeda completes raft of settlements in US generic Actos litigation
This article was originally published in Scrip
Takeda has now reached settlements with all of the defendants in patent infringement litigation that it had brought against filers of US ANDAs for generic versions of its big-selling oral antidiabetic, Actos (pioglitazone), and two combinations of this.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context